October 2018, Biological Biomarkers in Multiple Sclerosis by Prof Irina Elovaara and Nikolaos C Grigoriadis.
Need for biomarkers in MS:
• New therapeutic agents with variable mechanisms of action are available
• The complexity and heterogeneity of MS urges a more differentiated
defining of patients
• Personalized therapy: the information on disease and molecular biomarker profile of a particular patient will contribute to better understanding of their disease, diagnosis and factors that determine response to therapy
MD, PhD Neuroimmunology Unit, University of Tampere &
Department of Neurology, Tampere University Hospital, Finland
MD, PhD Laboratory of Experimental Neurology and Neuroimmunology & Department of Neurology AHEPA University Hospital, Aristotle University of Thessaloniki, Greece
Minimum two MS experts collaborate to produce an educational slide deck. These slide decks are presented (live) to ParadigMS members, peer reviewed and updated.
The slide decks are published on the ParadigMS website “on behalf of ParadigMS”.
Based on the slide decks, publications are produced. These publications are peer reviewed and published as consensus publications.
Regional (fe: Scandinavian countries, Benelux, …) or national events where state-of-the-art science is transferred to general neurologists and other care givers (nurses, etc) that are confronted with MS in their day to day practice.
Webinars can complement the educational events.
The educational slide decks, events and webinars can be important building blocks of accredited educational programs.